Second-line chemotherapy rechallenge in lung cancer patients: a Moroccan real-world study
{{output}}
Background: Immune checkpoint inhibitors are the go-to therapeutic option for relapsed non-small cell lung cancer (NSCLC) with unidentified oncogenic drivers when first-line platin doublet chemotherapy fails. Meanwhile, few optio... ...
